Navigation Links
HeartWare International Clinical Trial Shows 90% Survival at 180 Days
Date:4/24/2009

FRAMINGHAM, Mass. and SYDNEY, April 24 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) today announced updated results for its international clinical trial of the HeartWare(R) Left Ventricular Assist System. The results were presented by Dr. Martin Strueber, cardiothoracic surgeon at Hannover Medical School, at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) held in Paris this week. A full copy of the presentation was filed as part of a form 8-K with the U.S. Securities and Exchange Commission and can be accessed at www.sec.gov.

The data presented at ISHLT includes all 50 patients enrolled in the trial across 5 participating centers. The data show a survival rate of 90% at 6 months and a survival rate of approximately 86% at 12 months post implant*. On average, the patients were supported by the HeartWare(R) System for 300 days each. The cumulative duration of support across the group exceeded 41 years. The patients' quality of life showed significant improvement at all points post-implant and the rates of adverse events were relatively low despite the unusually long average duration of pump support across the patient group.

"These results appear again to confirm the benefits we believe to be inherent in the design of this device," said HeartWare CEO, Mr. Doug Godshall. "At the ISHLT meeting 12 months ago we reported a 90% survival among our initial patient cohort. It is pleasing to observe that this success rate has been maintained over a far larger patient group and over a longer period of time. We anticipate these positive data providing a meaningful stimulus as we make the system more broadly available in our International markets and as we accelerate enrolment in our US Bridge to Transplant clinical
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
3. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
4. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
5. Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009
6. VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
7. Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients
8. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
9. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
11. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
(Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:6/1/2015)... Ore. (PRWEB) June 01, 2015 ... (AHIP) announced today a new, interactive Affordable Care ... large employers. The course, called “Affordable Care Act ... professionals with the strategic and consultative insights necessary ... as they navigate the impacts of the ACA. ...
(Date:6/1/2015)... a leading web-base electronic healthcare software (EHR) is providing ... Louisiana. The entrepreneurial trio behind Sharenote, will travel to ... with the tools and resources to monitor key performance ... , Find out why Sharenote is the EHR ... 250 practices. , Four Day Schedule , ...
(Date:6/1/2015)... 2015 KC and Monica Craichy, Founders ... the best superfood products in the world ... Texas. , "Monica and I are excited to ... distributing Living Fuel Super Meals - SuperBerry®, SuperGreens and ... in Texas," KC Craichy said. "We have attempted to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... Northridge dentist , Dr. Michel Elyson, ... promotion on Invisalign for a limited time only. With ... to $3,700. Patients can find out about their candidacy ... the extent of correction they need. This promotion expires ... any other offer. , Invisalign has continued to ...
Breaking Medicine News(10 mins):Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2
... menstrual cycle into account when booking exam may cut need ... News) -- Using a blood test to pinpoint the optimal ... cycles could reduce the need for repeat scans, U.S. researchers ... scans during the follicular phase (days 3 to14) of the ...
... of successful events organised last year, a second Joint ... (ESC) and the European Association for the Study of ... organisations in Europe, will be held from 27-29 November ... Guangzhou. The theme is the Optimal Management of Diabetes, ...
... YORK, Nov. 20 Mallika Chopra, healthy living expert and ... natural stress relief products in the US, are teaming up ... program kicks off with advice from Chopra, to be posted ... the holidays without the stress or foreboding that typically comes ...
... and palliation in patients with pancreatic neuroendocrine tumors (PNTs), ... therapy, according to a largest of its kind study ... Journal of Radiation Oncology*Biology*Physics , the official journal of ... is a very rare form of pancreatic cancer that ...
... every 2 years or more, not annually, , FRIDAY, Nov. ... week, medical experts are revising the advice given women on ... should get their first screening for cervical cancer -- including ... in guidelines released Nov. 20 by the American College of ...
... 20 New data released today by Quest ... provider of employment-related drug testing services, reveal that drug testing ... general U.S. workforce has tracked sharp downward trends in cocaine ... 2009 that mirror similar drops shown by urine testing. Data ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:ESC to give talks on diabetes in 3 cities in China 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3Health News:Rare pancreatic cancer patients may live longer when treated with radiation therapy 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 3Health News:New Pap Test Guidelines: Start Later, Have Fewer 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 2Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 3Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 5Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 6Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 7Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 8Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 9Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 10
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... Detect™ IgM Capture ELISA is for the ... WNV recombinant antigens (WNRA) in serum as ... of West Nile virus infection in patients ... results must be confirmed by Plaque Reduction ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: